Opzelura (Ruxolitinib)

Ruxolitinib, the active ingredient in Opzelura, is a Janus kinase (JAK) inhibitor presented as a 1.5% w/w cream for topical use. It treats moderate-to-severe atopic dermatitis in adults and adolescents and non‑segmental vitiligo by reducing skin inflammation.

GNH USA supplies Opzelura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access for healthcare providers. The company adheres to stringent quality standards and offers comprehensive logistics support across multiple regions, including temperature‑controlled shipping where required.

Opzelura (ruxolitinib) is a topical JAK inhibitor indicated for specific dermatologic conditions.

- Moderate-to-severe atopic dermatitis in adults: improves skin lesions, reduces erythema and pruritus, and enhances quality of life by targeting cytokine‑driven inflammation. - Moderate-to-severe atopic dermatitis in adolescents: provides comparable reduction in inflammation and itch, supporting better sleep and daily functioning. - Non‑segmental vitiligo: promotes repigmentation of depigmented patches by locally inhibiting autoimmune activity and cytokine signaling in the skin.

Topical ruxolitinib can be associated with a range of adverse reactions, most of which are mild and localized.

Common Side Effects: - Application site irritation: mild redness or discomfort at the site of cream application. - Burning sensation: transient heat feeling during or after application. - Itching: occasional pruritus unrelated to underlying disease. - Dry skin: increased dryness or flaking of treated areas.

Serious or Rare Side Effects: - Skin infection: secondary bacterial or fungal infection at the treated site. - Allergic reaction: urticaria, swelling, or severe dermatitis requiring medical attention. - Systemic immunosuppression: rare systemic absorption leading to increased infection risk. - Malignancy risk: theoretical risk of skin cancer with prolonged use, monitored in clinical practice.

When using Opzelura, several precautions should be observed to ensure safety and maintain product efficacy.

- Avoid use on infected skin: do not apply to open wounds, active bacterial or fungal infections. - Limit application area: restrict to prescribed lesions and avoid excessive coverage. - Monitor for signs of infection: discontinue if severe redness, pus, or fever develop. - Pregnancy and lactation: safety not established; use only if potential benefit justifies potential risk. - Concomitant immunosuppressants: use with caution and under close medical supervision. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Opzelura may interact with other medicines, primarily through additive immunosuppressive effects or metabolic pathways.

Major Interactions (Avoid): - Systemic JAK inhibitors: combined use can markedly increase immunosuppression and infection risk. - Strong CYP3A4 inhibitors: may raise systemic ruxolitinib levels if absorbed, potentially enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: concurrent use may amplify local immunosuppression, requiring monitoring. - Phototherapy (UVB/UVA): may increase skin sensitivity and risk of irritation. - Other immunosuppressive agents: combined therapy warrants careful infection surveillance. - Antifungal or antiviral topical agents: assess for additive skin irritation.